Brazil's Pharmaceut?ical Market: Increase in Chronic and Lifestyle-?Associated Diseases to Boost Sales
![](/46/pdcnewsitem/03/26/72/GiRgSmGvJeUC3Jc.jpg)
Brazil has emerged as a manufacturing hub for pharmaceutical and biotechnology companies, with the pharma market forecast to grow from $12.4 billion in 2007 to $58.8 billion in 2020, at a Compound Annual Growth Rate (CAGR) of 12.7%, says research and consulting firm GlobalData.
The company’s latest report* states that the medical device market in Brazil will also see significant growth from $7.9 billion in 2012 to $13.1 billion by 2020, at a CAGR of 6.6%. In 2012, the main segments were ophthalmic devices ($1.5 billion), in vitro diagnostics devices ($0.9 billion) and diagnostic imaging devices ($0.8 billion).
Joshua Owide, Director of Healthcare Industry Dynamics, says: “The healthcare market in Brazil is primarily driven by an increase in disease burden, affordability, and access to primary care. However, healthcare does not cover the total population and therefore restricts further market growth.”
In fact, the Brazilian healthcare system comprises two subsystems: public and private. The country’s private healthcare insurance system is the second largest in the world, covering approximately 23.7% of the population.
Owide says: “Brazilian hospitals still have inadequate resources and are therefore unable to provide access to healthcare provisions for every citizen, especially to those in weaker economic sections.
“However, government initiatives, such as the increased availability of generic drugs through programmes including the People’s Pharmacy (Farmácia Popular), have contributed to the reduction of out-of-pocket expenditure and indirect price control, which stimulates competition from generics.”
Still, healthcare in Brazil carries the highest tax burden in comparison with other sectors of the economy, such as the education and financial system. Required taxes to the service provider can reach up to 28%, including federal and state taxes. This shows that the current tax system would require priority attention from the government, according to GlobalData.
*CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Brazil
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance